Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H14N2.2C4H6O6 |
Molecular Weight | 462.4052 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCC[C@H]1C2=CN=CC=C2
InChI
InChIKey=RFEJUZJILGIRHQ-OMDKHLBYSA-N
InChI=1S/C10H14N2.2C4H6O6/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;2*5-1(3(7)8)2(6)4(9)10/h2,4,6,8,10H,3,5,7H2,1H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t10-;2*1-,2-/m011/s1
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C10H14N2 |
Molecular Weight | 162.2316 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: www.inchem.org/documents/pims/chemical/nicotine.htmCurator's Comment: description was created based on several sources, including
https://cancercontrol.cancer.gov/brp/tcrb/monographs/1/index.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928221/
Sources: www.inchem.org/documents/pims/chemical/nicotine.htm
Curator's Comment: description was created based on several sources, including
https://cancercontrol.cancer.gov/brp/tcrb/monographs/1/index.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928221/
Nicotine is a natural alkaloid obtained from the dried leaves and stems of the nightshade family of pants, such as Nicotiana tabacum and Nicotiana rustica, where it occurs in concentrations of 0.5-8%. Cigarette tobacco varies in its nicotine content, but common blends contain 15-25 mg per cigarette, with a current trend towards lower levels. Nicotine is highly addictive substance, it exhibits a stimulant effect when adsorbed at 2 mg. Administration of higher doses could be harmful. Action of nicotine is mediated by nicotinic cholinergic receptors. Nicotine binds to the interface between two subunits of the receptors, opens the channel and allows the entry of sodium or calcium. The principal mediator of nicotine dependence is α4β2 nicotine receptor.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907589 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15528443 |
7.9 null [pKi] | ||
Target ID: CHEMBL1907594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22148173 |
260.0 nM [Ki] | ||
Target ID: CHEMBL2492 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15528443 |
3.0 µM [Ki] | ||
Target ID: CHEMBL2109238 |
|||
Target ID: Nicotinic acetylcholine receptors |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | NICORETTE Approved UseReduces withdrawal symptoms, including nicotine craving associated with quitting smoking Launch Date1984 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 ng/mL |
1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NICOTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 ng × h/mL |
1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NICOTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 min |
1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NICOTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
95% |
1 mg single, nasal dose: 1 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NICOTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
6 mg single, oral Highest studied dose |
healthy, 19 - 49 years n = 44 Health Status: healthy Condition: adult smokers Age Group: 19 - 49 years Sex: M+F Population Size: 44 Sources: |
Disc. AE: Bradycardia... AEs leading to discontinuation/dose reduction: Bradycardia (1 patient) Sources: |
4 mg single, oral Studied dose |
healthy, 19 - 49 years n = 44 Health Status: healthy Condition: adult smokers Age Group: 19 - 49 years Sex: M+F Population Size: 44 Sources: |
Disc. AE: Allergic dermatitis... AEs leading to discontinuation/dose reduction: Allergic dermatitis (1 patient) Sources: |
6 mg 1 times / hour steady, oral Highest studied dose Dose: 6 mg, 1 times / hour Route: oral Route: steady Dose: 6 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Disc. AE: Hypersensitivity, Nausea... AEs leading to discontinuation/dose reduction: Hypersensitivity (1 patient) Sources: Nausea (1 patient) |
8 mg 1 times / hour steady, oral Highest studied dose Dose: 8 mg, 1 times / hour Route: oral Route: steady Dose: 8 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Disc. AE: Depression, Nausea... AEs leading to discontinuation/dose reduction: Depression (1 patient) Sources: Nausea (grade 2-3, 2 patients) |
111 mg single, transdermal Overdose Dose: 111 mg Route: transdermal Route: single Dose: 111 mg Sources: |
healthy, 41 years n = 1 Health Status: healthy Condition: adult smoker Age Group: 41 years Sex: M Population Size: 1 Sources: |
Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5, 1 patient) Sources: |
84 mg 1 times / day steady, transdermal Highest studied dose Dose: 84 mg, 1 times / day Route: transdermal Route: steady Dose: 84 mg, 1 times / day Sources: |
healthy, adult n = 36 Health Status: healthy Condition: adult smokers Age Group: adult Sex: unknown Population Size: 36 Sources: |
Other AEs: Nausea... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bradycardia | 1 patient Disc. AE |
6 mg single, oral Highest studied dose |
healthy, 19 - 49 years n = 44 Health Status: healthy Condition: adult smokers Age Group: 19 - 49 years Sex: M+F Population Size: 44 Sources: |
Allergic dermatitis | 1 patient Disc. AE |
4 mg single, oral Studied dose |
healthy, 19 - 49 years n = 44 Health Status: healthy Condition: adult smokers Age Group: 19 - 49 years Sex: M+F Population Size: 44 Sources: |
Hypersensitivity | 1 patient Disc. AE |
6 mg 1 times / hour steady, oral Highest studied dose Dose: 6 mg, 1 times / hour Route: oral Route: steady Dose: 6 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Nausea | 1 patient Disc. AE |
6 mg 1 times / hour steady, oral Highest studied dose Dose: 6 mg, 1 times / hour Route: oral Route: steady Dose: 6 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Depression | 1 patient Disc. AE |
8 mg 1 times / hour steady, oral Highest studied dose Dose: 8 mg, 1 times / hour Route: oral Route: steady Dose: 8 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Nausea | grade 2-3, 2 patients Disc. AE |
8 mg 1 times / hour steady, oral Highest studied dose Dose: 8 mg, 1 times / hour Route: oral Route: steady Dose: 8 mg, 1 times / hour Sources: |
healthy, 19 - 50 years n = 50 Health Status: healthy Condition: adult smokers Age Group: 19 - 50 years Sex: M+F Population Size: 50 Sources: |
Death | grade 5, 1 patient Disc. AE |
111 mg single, transdermal Overdose Dose: 111 mg Route: transdermal Route: single Dose: 111 mg Sources: |
healthy, 41 years n = 1 Health Status: healthy Condition: adult smoker Age Group: 41 years Sex: M Population Size: 1 Sources: |
Nausea | 84 mg 1 times / day steady, transdermal Highest studied dose Dose: 84 mg, 1 times / day Route: transdermal Route: steady Dose: 84 mg, 1 times / day Sources: |
healthy, adult n = 36 Health Status: healthy Condition: adult smokers Age Group: adult Sex: unknown Population Size: 36 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
no | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 245.0 |
minor | |||
Page: 245.0 |
minor | |||
Sources: https://molpharm.aspetjournals.org/content/72/3/761 Page: - |
no | |||
Page: - |
yes | |||
Page: 245.0 |
yes | |||
Page: - |
yes | |||
Page: 60.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/17909004/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/20876810/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/20876810/ Page: - |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Modulation of phosphatidylinositol turnover on central nicotinic receptors. | 1997 Jul |
|
[Treatment outcome in tobacco dependence after nicotine replacement therapy and group therapy]. | 1999 |
|
Inducible, heterologous expression of human alpha7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line. | 1999 Apr 17 |
|
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant. | 1999 Feb 5 |
|
Pharmacological characterization of nicotine's interaction with cocaine and cocaine analogs. | 1999 Jun |
|
Chronic nicotine pretreatment protects the blood-brain barrier against nicotine-induced seizures in the rat. | 1999 Sep |
|
Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. | 2000 Apr |
|
Chick optic lobe contains a developmentally regulated alpha2alpha5beta2 nicotinic receptor subtype. | 2000 Aug |
|
Dermal exposure to pesticides modifies antioxidant enzymes in tissues of rats. | 2000 Jul |
|
Antioxidant effect of onion oil (Allium cepa. Linn) on the damages induced by nicotine in rats as compared to alpha-tocopherol. | 2000 Jul 27 |
|
Nicotine switches the form of H(2)O(2)-induced cell death from apoptosis to necrosis in U937 cells. | 2000 Jun 1 |
|
Neurobiological mechanisms by which nicotine mediates different types of anxiety. | 2000 Mar 30 |
|
Abstinence effects and reactivity to nicotine during 11 days of smoking deprivation. | 2000 May |
|
Kynurenic acid does not protect against nicotine-induced seizures in mice. | 2000 Nov-Dec |
|
Symposium overview: mechanism of action of nicotine on neuronal acetylcholine receptors, from molecule to behavior. | 2000 Oct |
|
Prenatal nicotine exposure is associated with an increase in [125I]epibatidine binding in discrete cortical regions in rats. | 2000 Oct |
|
Contributory role for nornicotine in nicotine neuropharmacology: nornicotine-evoked [3H]dopamine overflow from rat nucleus accumbens slices. | 2001 Dec 15 |
|
Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats. | 2001 Jan |
|
Nornicotine, a nicotine metabolite and tobacco alkaloid: desensitization of nicotinic receptor-stimulated dopamine release from rat striatum. | 2001 Sep 28 |
|
Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung. | 2002 Apr 8 |
|
Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. | 2002 Jan 31 |
|
Enhancement of cocaine-seeking behavior by repeated nicotine exposure in rats. | 2002 Jul |
|
Increased sensitivity to nicotine-induced seizures in mice expressing the L250T alpha 7 nicotinic acetylcholine receptor mutation. | 2002 Mar |
|
N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases. | 2002 Sep |
|
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | 2003 Jan 1 |
|
Nicotinic acetylcholine receptors and the regulation of neuronal signalling. | 2004 Jun |
Patents
Sample Use Guides
Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking, nicotine is available as a chewing gum, and is administered according to a schedule at doses 2-4 mg once every 2-4 hours. Nicotine is also available as a transdermal patch.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22148173
Functional activity of nicotine against hα4β2 nicotinic receptors was evaluated using the 86Rb+ ion flux assay in SH-EP1 cells, expressing hα4β2. The 86Rb+ efflux was measured using the “flip-plate” technique. Nicotine activated 86Rb+ efflux with EC50 of 290 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:18:00 GMT 2023
by
admin
on
Fri Dec 15 16:18:00 GMT 2023
|
Record UNII |
7892ZN5G41
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID401017270
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | |||
|
7892ZN5G41
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | |||
|
200-607-2
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | |||
|
11957628
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | |||
|
m7879
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | Merck Index | ||
|
806
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | |||
|
1306106
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | RxNorm | ||
|
65-31-6
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | |||
|
SUB22391
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | |||
|
100000086058
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY | |||
|
97238
Created by
admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SUBSTANCE->BASIS OF STRENGTH | |||
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |